GRIFOLS ADR 1/2/EO-50 (G0F) - Net Assets
Based on the latest financial reports, GRIFOLS ADR 1/2/EO-50 (G0F) has net assets worth €7.60 Billion EUR (≈ $8.89 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.71 Billion ≈ $23.05 Billion USD) and total liabilities (€12.11 Billion ≈ $14.16 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore GRIFOLS ADR 1/2/EO-50 (G0F) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.60 Billion |
| % of Total Assets | 38.57% |
| Annual Growth Rate | 0.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.64 |
GRIFOLS ADR 1/2/EO-50 - Net Assets Trend (2021–2025)
This chart illustrates how GRIFOLS ADR 1/2/EO-50's net assets have evolved over time, based on quarterly financial data. Explore GRIFOLS ADR 1/2/EO-50 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Net Assets for GRIFOLS ADR 1/2/EO-50 (2021–2025)
The table below shows the annual net assets of GRIFOLS ADR 1/2/EO-50 from 2021 to 2025. For live valuation and market cap data, see GRIFOLS ADR 1/2/EO-50 (G0F) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €7.60 Billion ≈ $8.89 Billion |
-11.67% |
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
+14.55% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
-5.80% |
| 2022-12-31 | €7.98 Billion ≈ $9.32 Billion |
+9.01% |
| 2021-12-31 | €7.32 Billion ≈ $8.55 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GRIFOLS ADR 1/2/EO-50's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 59.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €300.00 Million | 5.69% |
| Other Components | €4.97 Billion | 94.31% |
| Total Equity | €5.27 Billion | 100.00% |
GRIFOLS ADR 1/2/EO-50 Competitors by Market Cap
The table below lists competitors of GRIFOLS ADR 1/2/EO-50 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GlaxoSmithKline Pharmaceuticals Limited
NSE:GLAXO
|
$4.21 Billion |
|
Companhia Energética de Minas Gerais
MX:CIGN
|
$4.21 Billion |
|
Fujian Anjoy Foods Co Ltd
SHG:603345
|
$4.21 Billion |
|
Shenzhen Hopewind Elec Co Ltd
SHG:603063
|
$4.21 Billion |
|
Zeta Global Holdings Corp
NYSE:ZETA
|
$4.21 Billion |
|
Seazen Holdings Co Ltd
SHG:601155
|
$4.21 Billion |
|
Masan Group Corp
VN:MSN
|
$4.20 Billion |
|
Hanmi Pharm Co Ltd
KO:128940
|
$4.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GRIFOLS ADR 1/2/EO-50's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,883,727,000 to 5,271,000,000, a change of -612,727,000 (-10.4%).
- Net income of 402,000,000 contributed positively to equity growth.
- Dividend payments of 128,000,000 reduced retained earnings.
- Other factors decreased equity by 886,727,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €402.00 Million | +7.63% |
| Dividends Paid | €128.00 Million | -2.43% |
| Other Changes | €-886.73 Million | -16.82% |
| Total Change | €- | -10.41% |
Book Value vs Market Value Analysis
This analysis compares GRIFOLS ADR 1/2/EO-50's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €8.14 | €4.26 | x |
| 2022-12-31 | €8.33 | €4.26 | x |
| 2023-12-31 | €7.91 | €4.26 | x |
| 2024-12-31 | €8.65 | €4.26 | x |
| 2025-12-31 | €7.74 | €4.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GRIFOLS ADR 1/2/EO-50 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.34%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 3.74x
- Recent ROE (7.63%) is above the historical average (3.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.42% | 3.83% | 0.26x | 3.48x | €-363.63 Million |
| 2022 | 3.28% | 3.05% | 0.29x | 3.76x | €-379.82 Million |
| 2023 | 0.78% | 0.64% | 0.31x | 3.91x | €-494.84 Million |
| 2024 | 2.67% | 2.18% | 0.34x | 3.64x | €-431.37 Million |
| 2025 | 7.63% | 5.34% | 0.38x | 3.74x | €-125.10 Million |
Industry Comparison
This section compares GRIFOLS ADR 1/2/EO-50's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $196,862,756,222
- Average return on equity (ROE) among peers: 15.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GRIFOLS ADR 1/2/EO-50 (G0F) | €7.60 Billion | 3.42% | 1.59x | $4.21 Billion |
| Bayer AG NA (BAYN) | $47.52 Billion | 8.61% | 1.66x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $463.79 Million | 3.71% | 0.64x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $19.52 Billion | 19.03% | 0.35x | $10.04 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| Grifols S.A (G0FB) | $3.73 Billion | 14.63% | 1.72x | $4.42 Billion |
| GSK PLC SP. ADR/2 NEW (GS70) | $12.79 Billion | 38.52% | 3.61x | $101.34 Billion |
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | $1.00 Billion | 32.83% | 0.62x | $8.31 Billion |
| Sanofi (SNW2) | $59.11 Billion | 4.75% | 0.91x | $105.72 Billion |
| ASTELLAS PHARMA UNSP.ADR (YPHA) | $1.60 Trillion | 1.07% | 1.24x | $19.55 Billion |
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more